TY - JOUR
T1 - Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype
AU - Abrahamov, A.
AU - Elstein, D.
AU - Zimran, A.
AU - Farber, B.
AU - Glaser, Y.
AU - Gross-Tsur, V.
AU - Hadas-Halpern, I.
AU - Ronen, S.
AU - Horowitz, M.
AU - Tafakjdi, M.
N1 - Funding Information:
This study was supported by grants from the Helen-Manuel Foundation and the Israeli Science Foundation administered by the Israel Academy of Sciences and Humanities (AZ).
PY - 1995/10/14
Y1 - 1995/10/14
N2 - Gaucher's disease is the most prevalent sphingolipid storage disease, characterised by substantial genetic and phenotypic variability. Cardiac manifestations are rare. We report 12 Arab Gaucher's disease patients, 2-20 years of age, who presented with oculomotor apraxia but only slight classic signs of the disease. All but the youngest had calcifications of the aortic or mitral valves or both. All these patients were homozygous for the rare point mutation D409H (1342C). Valvular calcifications increased with age and showed progression during 2 years of follow-up. Two of the oldest patients underwent aortic valve replacement, and one sibling had died suddenly at age 16, before this study. Corneal opacities were another common feature. The potentially fatal course of this Gaucher's disease variant, and the availability of a reliable PCR-based method for heterozygote detection, mean that population screening and genetic counselling in the geographic area at risk are important. Affected individuals should be closely monitored by echocardiography to gauge the need for valve replacement. The potential of enzyme replacement to prevent these cardiac complications cannot be ascertained at present, because of the high cost of therapy.
AB - Gaucher's disease is the most prevalent sphingolipid storage disease, characterised by substantial genetic and phenotypic variability. Cardiac manifestations are rare. We report 12 Arab Gaucher's disease patients, 2-20 years of age, who presented with oculomotor apraxia but only slight classic signs of the disease. All but the youngest had calcifications of the aortic or mitral valves or both. All these patients were homozygous for the rare point mutation D409H (1342C). Valvular calcifications increased with age and showed progression during 2 years of follow-up. Two of the oldest patients underwent aortic valve replacement, and one sibling had died suddenly at age 16, before this study. Corneal opacities were another common feature. The potentially fatal course of this Gaucher's disease variant, and the availability of a reliable PCR-based method for heterozygote detection, mean that population screening and genetic counselling in the geographic area at risk are important. Affected individuals should be closely monitored by echocardiography to gauge the need for valve replacement. The potential of enzyme replacement to prevent these cardiac complications cannot be ascertained at present, because of the high cost of therapy.
UR - http://www.scopus.com/inward/record.url?scp=0029144034&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(95)91688-1
DO - 10.1016/S0140-6736(95)91688-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0029144034
VL - 346
SP - 1000
EP - 1003
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 8981
ER -